Erratum: The heme oxygenase system attenuates pancreatic lesions and improves insulin sensitivity and glucose metabolism in deoxycorticosterone acetate hypertension (The American Journal of Physiology - Regulatory, Integrative and Comparative Physiology (2010) 298, (R211-R223) DOI: 10.1152/ajpregu.91000.2008);The heme oxygenase system attenuates pancreatic lesions and improves insulin sensitivity and glucose metabolism in deoxycorticosterone acetate hypertension

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 1, 2010, Pages

  Ndisang, Joseph Fomusi ^a   Jadhav, Ashok ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adiponectin; Insulin sensitivity; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ADIPONECTIN; BILIRUBIN; CATALASE; CHROMIUM DERIVATIVE; CHROMIUM MESOPORPHYRIN; CYCLIC AMP; CYCLIC GMP; DEOXYCORTICOSTERONE ACETATE; FERRITIN; GLUCOSE; HEME OXYGENASE; HEME OXYGENASE 1; HEMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HISTOPATHOLOGY; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 73549113296     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.zh6-7193-corr.2010     Document Type: Erratum

References (60)

1. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60: 79-127, 2008.
2. Adult Treatment Panel III. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. JAMA 285: 2486-2497, 2001.
3. Auerbach A, Sachs F. Patch clamp studies of single ionic channels. Annu Rev Biophys Bioeng 13: 269-302, 1984.
4. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99: 16093-16098, 2002.
5. Bennett BL, Satoh Y, Lewis AJ. JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 3: 420-425, 2003.
6. Boscaro M, Ronconi V, Turchi F, Giacchetti G. Diagnosis and management of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 15: 332-338, 2008.
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
8. Bruce CR, Carey AL, Hawley JA, Febbraio MA. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. Diabetes 52: 2338-2345, 2003.
9. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91: 3457-3463, 2006.
10. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.
11. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 5: 106-109, 2003.
12. Dai S, Fraser H, McNeill JH. Effects of deoxycorticosterone acetate on glucose metabolism in nondiabetic and streptozotocin-diabetic rats. Can J Physiol Pharmacol 70: 1468-1472, 1992.
13. Dai S, McNeill JH. Myocardial performance of STZ-diabetic DOCA-hypertensive rats. Am J Physiol Heart Circ Physiol 263: H1798-H1805, 1992.
14. Delanty N, Reilly MP, Pratico D, Lawson JA, McCarthy JF, Wood AE, Ohnishi ST, Fitzgerald DJ, FitzGerald GA. 8-epi PGF2α generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 95: 2492-2499, 1997.
15. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, Veglio F, Mulatero P. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 20: 855-861, 2007.
16. Fallo F, Federspil G, Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Diab Rep 8: 42-47, 2008.
17. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91: 454-459, 2006.
18. Fukunaga M, Yura T, Badr KF. Stimulatory effect of 8-Epi-PGF2α, an F2-isoprostane, on endothelin-1 release. J Cardiovasc Pharmacol 26, Suppl 3: S51-S52, 1995.
19. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25: 177-186, 2007.
20. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000.
21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752, 2005.
22. Haluzik M. Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance. Curr Opin Investig Drugs 6: 988-993, 2005.
23. Henningsson R, Alm P, Ekstrom P, Lundquist I. Heme oxygenase and carbon monoxide: regulatory roles in islet hormone release: a biochemical, immunohistochemical, and confocal microscopic study. Diabetes 48: 66-76, 1999.
24. Henningsson R, Alm P, Lundquist I. Occurrence and putative hormone regulatory function of a constitutive heme oxygenase in rat pancreatic islets. Am J Physiol Cell Physiol 273: C703-C709, 1997.
25. Hintze KJ, Theil EC. DNA and mRNA elements with complementary responses to hemin, antioxidant inducers, and iron control ferritin-L expression. Proc Natl Acad Sci USA 102: 15048-15052, 2005.
26. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M, Hirata Y. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local reninangiotensin system. Endocrinology 148: 1688-1696, 2007.
27. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens 17: 597-603, 2004.
28. Jadhav A, Torlakovic E, Ndisang JF. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. Am J Physiol Renal Physiol 296: F521-F534, 2009.
29. Jadhav A, Torlakovic E, Ndisang JF. Interaction among heme oxygenase, nuclear factor-κB, and transcription activating factors in cardiac hypertrophy in hypertension. Hypertension 52: 910-917, 2008.
30. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 280: L1067-L1082, 2001.
31. Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, Balla G. Pro-oxidant and cytotoxic effects of circulating heme. Blood 100: 879-887, 2002.
32. Kai H, Mori T, Tokuda K, Takayama N, Tahara N, Takemiya K, Kudo H, Sugi Y, Fukui D, Yasukawa H, Kuwahara F, Imaizumi T. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res 29: 711-718, 2006.
33. Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, Itoh N, Ishimaru S, Ohtsuka Y, Nishimura M. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 339: 624-632, 2006.
34. Kaneto H, Matsuoka TA, Katakami N, Kawamori D, Miyatsuka T, Yoshiuchi K, Yasuda T, Sakamoto K, Yamasaki Y, Matsuhisa M. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 7: 674-686, 2007.
35. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA, Matsuhisa M, Yamasaki Y. Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic β-cell dysfunction and insulin resistance. Int J Biochem Cell Biol 38: 782-793, 2006.
36. Kiemer AK, Vollmar AM, Bilzer M, Gerwig T, Gerbes AL. Atrial natriuretic peptide reduces expression of TNF-α mRNA during reperfusion of the rat liver upon decreased activation of NF-κB and AP-1. J Hepatol 33: 236-246, 2000.
37. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863-25866, 2002.
38. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, Aronow WS, Ikehara S, Abraham NG. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 57: 1526-1535, 2008.
39. Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and aldosterone stimulating NF-κB and AP-1 activation in hepatic fibrosis of rat. Regul Pept 138: 15-25, 2007.
40. 2+ signals between pancreatic β-cells. Am J Physiol Endocrinol Metab 285: E1055-E1063, 2003.
41. Lutton JD, Abraham NG, Drummond GS, Levere RD, Kappas A. Zinc porphyrins: potent inhibitors of hematopoieses in animal and human bone marrow. Proc Natl Acad Sci USA 94: 1432-1436, 1997.
42. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 2906-2912, 2005.
43. Mosen H, Salehi A, Alm P, Henningsson R, Jimenez-Feltstrom J, Ostenson CG, Efendic S, Lundquist I. Defective glucose-stimulated insulin release in the diabetic Goto-Kakizaki (GK) rat coincides with reduced activity of the islet carbon monoxide signaling pathway. Endocrinology 146: 1553-1558, 2005.
44. Mosen H, Salehi A, Henningsson R, Lundquist I. Nitric oxide inhibits, and carbon monoxide activates, islet acid α-glucoside hydrolase activities in parallel with glucose-stimulated insulin secretion. J Endocrinol 190: 681-693, 2006.
45. Ndisang JF, Jadhav A. Heme oxygenase system enhances insulin sensitivity and glucose metabolism in streptozotocin-induced diabetes. Am J Physiol Endocrinol Metab 296: E829-E841, 2009.
46. Ndisang JF, Jadhav A. Up-regulating the hemeoxygenase system enhances insulin sensitivity and improves glucose metabolism in insulin-resistant diabetes in Goto-Kakizaki rats. Endocrinology 150: 2627-2636, 2009.
47. Ndisang JF, Lane N, Jadhav A. Crosstalk between the heme oxygenase system, aldosterone, and phospholipase C in hypertension. J Hypertens 26: 1188-1199, 2008.
48. Ndisang JF, Lane N, Jadhav A. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology 150: 2098-2108, 2009.
49. Ndisang JF, Lane N, Jadhav A. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 296: E1029-E1041, 2009.
50. Ndisang JF, Zhao W, Wang R. Selective regulation of blood pressure by heme oxygenase-1 in hypertension. Hypertension 40: 315-321, 2002.
51. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102: 1296-1301, 2000.
52. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334: 374-381, 1996.
53. Rodriguez JA, Lopez JM, Biglieri EG. DOCA test for aldosteronism: its usefulness and implications. Hypertension 3: II-102-II-106, 1981.
54. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286: H1597-H1602, 2004.
55. Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 88: 63-82, 2004.
56. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosteroneinduced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773-1781, 2002.
57. Turkseven S, Kruger A, Mingone CJ, Kaminski P, Inaba M, Rodella LF, Ikehara S, Wolin MS, Abraham NG. Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. Am J Physiol Heart Circ Physiol 289: H701-H707, 2005.
58. Ushiyama M, Morita T, Katayama S. Carbon monoxide regulates blood pressure cooperatively with nitric oxide in hypertensive rats. Heart Vessels 16: 189-195, 2002.
59. Vettor R, Milan G, Rossato M, Federspil G. Adipocytokines and insulin resistance. Aliment Pharmacol Ther 22, Suppl 2: 3-10, 2005.
60. Vreman HJ, Ekstrand BC, Stevenson DK. Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity. Pediatr Res 33: 195-200, 1993.